Emmaus Life Sciences, Inc. (EMMA) Financial Statements (2025 and earlier)
Company Profile
| Business Address |
21250 HAWTHORNE BOULEVARD, SUITE 800 TORRANCE, CA 90503 |
| State of Incorp. | DE |
| Fiscal Year End | December 31 |
| Industry (SIC) | 2834 - Pharmaceutical Preparations (benchmarking) |
| More info | Complete Financial Analysis Financial Benchmarking |
Balance Sheet (Statement of Financial Position) ($ in thousands)Annual | Quarterly
| 3/31/2025 Q1 | 12/31/2024 Q4 | 9/30/2024 Q3 | 6/30/2024 Q2 | 3/31/2024 Q1 | 12/31/2023 Q4 | 9/30/2023 Q3 | |||
|---|---|---|---|---|---|---|---|---|---|
| ASSETS | |||||||||
| Current Assets | |||||||||
| Cash, cash equivalents, and short-term investments | 1,389 | 1,255 | 1,525 | 1,712 | 2,547 | 1,505 | |||
| Cash and cash equivalent | 1,389 | 1,255 | 1,525 | 1,712 | 2,547 | 1,505 | |||
| Receivables | 2,623 | 4,938 | 4,598 | 2,990 | 5,524 | 4,587 | |||
| Inventory, net of allowances, customer advances and progress billings | 1,635 | 1,610 | 1,628 | 1,527 | 1,711 | 1,650 | |||
| Inventory | 1,635 | 1,610 | 1,628 | 1,527 | 1,711 | 1,650 | |||
| Prepaid expense | 272 | 364 | 279 | 442 | 536 | 736 | |||
| Other current assets | 226 | 817 | 654 | 762 | 596 | 647 | |||
| Other undisclosed current assets | 622 | 220 | 328 | 411 | 595 | 132 | |||
| Total current assets: | 6,767 | 9,204 | 9,012 | 7,844 | 11,509 | 9,257 | |||
| Noncurrent Assets | |||||||||
| Operating lease, right-of-use asset | 1,530 | 1,719 | 1,903 | 2,082 | 2,337 | 2,510 | |||
| Property, plant and equipment | 46 | 49 | 54 | 57 | 59 | 60 | |||
| Long-term investments and receivables | 17,737 | ||||||||
| Long-term investments | 17,737 | ||||||||
| Other noncurrent assets | 222 | 312 | 308 | 310 | 296 | 293 | |||
| Other undisclosed noncurrent assets | 15,037 | 16,059 | 14,662 | 19,250 | 20,978 | 17,596 | |||
| Total noncurrent assets: | 16,835 | 18,139 | 16,927 | 21,699 | 23,670 | 38,196 | |||
| TOTAL ASSETS: | 23,602 | 27,343 | 25,939 | 29,543 | 35,179 | 47,453 | |||
| LIABILITIES AND EQUITY | |||||||||
| Liabilities | |||||||||
| Current Liabilities | |||||||||
| Accounts payable and accrued liabilities, including: | 16,926 | 18,707 | 18,920 | 18,187 | 17,725 | 16,285 | |||
| Accounts payable | 5,175 | 6,489 | 7,214 | 6,565 | 5,887 | 4,805 | |||
| Accrued liabilities | 7,732 | 7,864 | 8,163 | 8,519 | 8,174 | 8,164 | |||
| Other undisclosed accounts payable and accrued liabilities | 4,019 | 4,354 | 3,543 | 3,103 | 3,664 | 3,316 | |||
| Debt | 17,014 | 16,205 | 16,329 | 16,588 | 16,383 | ||||
| Derivative instruments and hedges, liabilities | 8 | 30 | 69 | 74 | 65 | 522 | |||
| Other liabilities | 16,557 | 15,650 | 14,353 | 14,858 | 14,681 | 14,400 | |||
| Other undisclosed current liabilities | 13,050 | 13,539 | 14,354 | 12,721 | 12,653 | 29,710 | |||
| Total current liabilities: | 63,555 | 64,131 | 64,025 | 62,428 | 61,507 | 60,917 | |||
| Noncurrent Liabilities | |||||||||
| Liabilities, other than long-term debt | 14,280 | 14,752 | 16,692 | 18,528 | 19,202 | 19,310 | |||
| Other liabilities | 13,465 | 13,676 | 15,370 | 16,967 | 17,363 | 17,240 | |||
| Operating lease, liability | 815 | 1,076 | 1,322 | 1,561 | 1,839 | 2,070 | |||
| Other undisclosed noncurrent liabilities | 2,246 | 2,241 | 2,236 | 2,231 | 2,226 | 3,556 | |||
| Total noncurrent liabilities: | 16,526 | 16,993 | 18,928 | 20,759 | 21,428 | 22,866 | |||
| Total liabilities: | 80,081 | 81,124 | 82,953 | 83,187 | 82,935 | 83,783 | |||
| Equity | |||||||||
| Equity, attributable to parent | (56,479) | (53,781) | (57,014) | (53,644) | (47,756) | (36,330) | |||
| Common stock | 64 | 64 | 64 | 62 | 62 | 54 | |||
| Additional paid in capital | 225,896 | 225,867 | 225,839 | 225,503 | 225,333 | 222,439 | |||
| Accumulated other comprehensive loss | (2,995) | (2,016) | (3,394) | (1,870) | (160) | (1,503) | |||
| Accumulated deficit | (262,575) | (260,827) | (262,654) | (260,470) | (256,122) | (257,320) | |||
| Receivable from shareholders or affiliates for issuance of capital stock | (16,869) | (16,869) | (16,869) | (16,869) | (16,869) | ||||
| Total equity: | (56,479) | (53,781) | (57,014) | (53,644) | (47,756) | (36,330) | |||
| TOTAL LIABILITIES AND EQUITY: | 23,602 | 27,343 | 25,939 | 29,543 | 35,179 | 47,453 | |||
Income Statement (P&L) ($ in thousands)Annual | Quarterly
| 3/31/2025 Q1 | 12/31/2024 Q4 | 9/30/2024 Q3 | 6/30/2024 Q2 | 3/31/2024 Q1 | 12/31/2023 Q4 | 9/30/2023 Q3 | ||
|---|---|---|---|---|---|---|---|---|
| Revenues | 3,292 | 5,478 | 5,377 | 2,506 | 7,067 | 5,018 | ||
| Cost of revenue | (309) | (394) | (241) | (257) | (191) | (214) | ||
| Gross profit: | 2,983 | 5,084 | 5,136 | 2,249 | 6,876 | 4,804 | ||
| Operating expenses | (3,540) | (4,263) | (4,554) | (4,989) | (5,521) | (4,780) | ||
| Operating income (loss): | (557) | 821 | 582 | (2,740) | 1,355 | 24 | ||
| Nonoperating income (expense) (Gain (Loss), Foreign Currency Transaction, before Tax) | (137) | (117) | 75 | 31 | 1,460 | (821) | ||
| Interest and debt expense | (878) | (2,353) | (2,556) | |||||
| Income (loss) from continuing operations before equity method investments, income taxes: | (694) | 704 | 657 | (3,587) | 462 | (3,353) | ||
| Loss from equity method investments | (366) | (381) | ||||||
| Other undisclosed income (loss) from continuing operations before income taxes | (1,048) | 1,122 | (2,810) | (768) | 1,001 | 3,839 | ||
| Income (loss) from continuing operations before income taxes: | (1,742) | 1,826 | (2,153) | (4,355) | 1,097 | 105 | ||
| Income tax expense (benefit) | (6) | 1 | (31) | 7 | 112 | (38) | ||
| Net income (loss) available to common stockholders, diluted: | (1,748) | 1,827 | (2,184) | (4,348) | 1,209 | 67 | ||
Comprehensive Income ($ in thousands)Annual | Quarterly
| 3/31/2025 Q1 | 12/31/2024 Q4 | 9/30/2024 Q3 | 6/30/2024 Q2 | 3/31/2024 Q1 | 12/31/2023 Q4 | 9/30/2023 Q3 | ||
|---|---|---|---|---|---|---|---|---|
| Net income (loss): | (1,748) | 1,827 | (2,184) | (4,348) | 1,209 | 67 | ||
| Other comprehensive income (loss) | (979) | 1,378 | (1,524) | (1,710) | 1,343 | (1,389) | ||
| Comprehensive income (loss), net of tax, attributable to parent: | (2,727) | 3,205 | (3,708) | (6,058) | 2,552 | (1,322) | ||
Statements Sources
The financial statements are based on the Company's filings with the U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.